Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Asset Writedowns and Impairment (2019 - 2022)

ImmunityBio (IBRX) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $10.7 million as the latest value for Q3 2020.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $10.7 million in Q3 2020 year-over-year; TTM through Dec 2022 was $10.7 million, a 6.36% decrease, with the full-year FY2022 number at $681000.0, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $10.7 million for Q3 2020 at ImmunityBio, up from $724000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $10.7 million in Q3 2020 to a low of $724000.0 in Q4 2019.